KANAMYCIN SULFATE

Bezeichnung:KANAMYCIN SULFATE

CAS-Nr70560-51-9

Englisch Name:KANAMYCIN SULFATE

CBNumberCB5722316

SummenformelC18H38N4O15S

Molgewicht582.58

MOL-Datei70560-51-9.mol

KANAMYCIN SULFATE physikalisch-chemischer Eigenschaften

storage temp.	2-8°C
Löslichkeit	H₂O: 10-50 mg/mL As a stock solution. Stock solutions should be stored at 2-8°C. Stable at 37°C for 5 days.
Aggregatzustand	powder
Farbe	white to off-white
BRN	3874279
CAS Datenbank	70560-51-9(CAS DataBase Reference)

Sicherheit

Kennzeichnung gefährlicher	Xi,T
R-Sätze:	61
S-Sätze:	22-24/25-53-45-36/37/39
WGK Germany	3
RTECS-Nr.	NZ3225030

Gefahreninformationscode (GHS)

KANAMYCIN SULFATE Chemische Eigenschaften,Einsatz,Produktion Methoden

R-Sätze Betriebsanweisung:
R61:Kann das Kind im Mutterleib schädigen.
S-Sätze Betriebsanweisung:
S22:Staub nicht einatmen.
S24/25:Berührung mit den Augen und der Haut vermeiden.
S53:Exposition vermeiden - vor Gebrauch besondere Anweisungen einholen.
S45:Bei Unfall oder Unwohlsein sofort Arzt zuziehen (wenn möglich, dieses Etikett vorzeigen).
S36/37/39:Bei der Arbeit geeignete Schutzkleidung,Schutzhandschuhe und Schutzbrille/Gesichtsschutz tragen.
Originator
Kantrex,Bristol,US,1958
Verwenden
Kanamycin Sulfate is an aminoglycoside-antibiotic with broad antibacterial spectrum.
Manufacturing Process
As described in US Patent 2,931,798, Streptomyces kanamyceticus (K2-J) was first cultured in shake flasks in the following media: (a) 0.75% meat extract, 0.75% peptone, 0.3% NaCl, with 1.0% of starch, dextrin, maltose, glucose, lactose, sucrose or glycerol; or (b) 2.0% soybean meal, 0.05% KCl, 0.05% MgSO4 · 7H2O, 0.5% NaCl, 0.2% NaNO3, with 1.0% of starch, dextrin, maltose, glucose, lactose, sucrose or glycerol. The initial pH of all media was adjusted to 7.0. After 24 to 48 hours shaking in some cases the pH decreased to about 6.0 to 6.8, but from 72 to 120 hours the pH rose and became 7.5 to 8.6. The production of kanamycin was apparent after 48 hours and, depending on the media; the maximum production was found after 72 to 120 hours.
The yield was highest with starch or dextrin, intermediate and about the same with sucrose, glucose, maltose and lactose and poorest with glycerol. Kanamycin was produced by media containing soybean meal, peanut meal, cottonseed meal, corn steep liquor, peptone, yeast extract or meat extract, with or without sodium nitrate. Commercially available soybean meal was recognized to be one of the best nitrogen sources. The addition of corn steep liquor, peptone, yeast extract or nitrate to the soybean meal promoted the production of kanamycin.
The brownish white kanamycin (5 g) was dissolved in 50 ml of 60% aqueous methanol, insoluble material was removed and to the filtrate 40 ml of 60% aqueous methanol containing 2,000 mg of ammonium sulfate was added, and the precipitated kanamycin sulfate was collected, washed with 50 ml of 80% aqueous methanol, and dried. Thus, 4.5 g of kanamycin sulfate was obtained as a light brownish powder.
Therapeutic Function
Antibacterial
Clinical Use
Kanamycin Sulfate was isolated in 1957 by Umezawaand coworkers from Streptomyces kanamyceticus. Its activityagainst mycobacteria and many intestinal bacteria, aswell as several pathogens that show resistance to other antibiotics,brought a great deal of attention to this antibiotic.As a result, kanamycin was tested and released for medicaluse in a very short time.
The use of kanamycin in the United States usually is restrictedto infections of the intestinal tract (e.g., bacillarydysentery) and to systemic infections arising from Gramnegativebacilli (e.g., Klebsiella, Proteus, Enterobacter, andSerratia spp.) that have developed resistance to other antibiotics.It has also been recommended for preoperative antisepsisof the bowel. It is absorbed poorly from the intestinaltract; consequently, systemic infections must be treated byintramuscular or (for serious infections) intravenous injections.These injections are rather painful, and the concomitantuse of a local anesthetic is indicated. The use ofkanamycin in the treatment of TB has not been widely advocatedsince the discovery that mycobacteria develop resistancevery rapidly. In fact, both clinical experience andexperimental work indicate that kanamycin developscross-resistance in the tubercle bacilli with dihydrostreptomycin,viomycin, and other antitubercular drugs. Like streptomycin,kanamycin may cause decreased or complete lossof hearing. On development of such symptoms, its useshould be stopped immediately.

KANAMYCIN SULFATE Upstream-Materialien And Downstream Produkte

KANAMYCIN SULFATE Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

70560-51-9, KANAMYCIN SULFATE Verwandte Suche:

Send Inquriy